EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 7

Submission ID: 150825

Submission UUID: 263ffdff-7bc7-4e6c-bdb1-850fcc17ecd0

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=vlIS5Ag-u8wZbb_fgYZ8x_NssTw9L3H99cEu_4xGvyc

Created: Wed, 09/03/2025 - 15:15

Completed: Wed, 09/03/2025 - 15:15

Changed: Wed, 09/03/2025 - 15:15

Remote IP address: 10.208.24.230

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

EBV is associated with the development of post-transplant lymphoproliferative disease (PTLD), a serious complication of solid organ and bone marrow transplantation. To understand the immune response to EBV in transplant recipients we analyzed the T cell response in EBV seropositive transplant recipients with no evidence of EBV disease and in transplant recipients with chronic (3-6 months) EBV DNAemia (CED). We detected a significantly reduced proportion of IL-2/IFN-g polyfunctional CD4+ T effector memory (TEM) cells in the CED group compared to the controls. CED CD8+ T cells had a higher proportion of TEMRA cells but significantly fewer of these were IL-2+TEMRA cells. Similarly, there were fewer IL-2+, TNF-a+, and IL-2/TNF-a+ polyfunctional TEM CD8+ T cells in the CED group compared to controls. Moreover, the CED group had fewer clonally expanded TEMRA compared to the control group. To investigate the molecular underpinnings of these differences we performed scRNAseq on PBMC after stimulation with EBV latent cycle peptides. Using UMAP we identified 19 clusters that include naïve, transitional, TEM, TEMRA, and central memory CD8+ T cells. CED CD8+ TEMRA and TEM cells express higher levels of exhaustion genes (LAG3, TIGIT, TOX, HAVCR2) compared to the control group. In contrast, CD8+ T cells from controls showed upregulation of T cell activation and co-stimulation genes (ICOS, CD2, CD28, CD27). KEGG and Gene Ontology Term Biological Processes analysis reveals enrichment of pathways for ribosomal activity, cell proliferation, and negative regulation of T cell apoptosis in CD8+ T cells from controls, while CD8+ T cells from the CED group were enriched for pathways related to apoptotic signaling, negative regulation of T cell activation, and EBV infection.  These data pinpoint specific functional immune alterations in  the T cell compartment of individuals that are unable to mount effective responses to EBV.